Cooke & Bieler LP decreased its position in shares of Perrigo Company plc (NYSE:PRGO) by 2.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 84,123 shares of the company’s stock after selling 2,455 shares during the period. Cooke & Bieler LP owned 0.06% of Perrigo worth $7,332,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Dupont Capital Management Corp acquired a new position in Perrigo during the fourth quarter worth approximately $104,000. Quantitative Systematic Strategies LLC acquired a new position in Perrigo during the fourth quarter worth approximately $213,000. V Wealth Management LLC acquired a new position in Perrigo during the fourth quarter worth approximately $214,000. Lourd Capital LLC acquired a new position in Perrigo during the fourth quarter worth approximately $216,000. Finally, Allianz Asset Management GmbH acquired a new position in Perrigo during the third quarter worth approximately $217,000. 83.27% of the stock is currently owned by institutional investors.
In other Perrigo news, VP Todd W. Kingma sold 1,500 shares of the business’s stock in a transaction on Thursday, December 28th. The stock was sold at an average price of $88.52, for a total transaction of $132,780.00. Following the sale, the vice president now directly owns 19,565 shares in the company, valued at $1,731,893.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP John Wesolowski sold 388 shares of the business’s stock in a transaction on Wednesday, November 29th. The stock was sold at an average price of $87.20, for a total value of $33,833.60. Following the sale, the executive vice president now owns 248 shares in the company, valued at $21,625.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 4,051 shares of company stock worth $355,370. 6.90% of the stock is owned by company insiders.
Several research analysts have weighed in on PRGO shares. BidaskClub downgraded Perrigo from a “hold” rating to a “sell” rating in a research note on Thursday, October 26th. Cantor Fitzgerald set a $107.00 target price on Perrigo and gave the company a “buy” rating in a research note on Friday, October 20th. Jefferies Group set a $71.00 target price on Perrigo and gave the company a “hold” rating in a research note on Sunday, October 29th. Royal Bank of Canada upgraded Perrigo from an “underperform” rating to a “sector perform” rating and lifted their target price for the company from $64.00 to $86.00 in a research note on Friday, November 10th. Finally, Morgan Stanley lifted their target price on Perrigo from $79.00 to $92.00 and gave the company an “equal weight” rating in a research note on Friday, November 10th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and ten have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $93.47.
Shares of Perrigo Company plc (NYSE:PRGO) opened at $85.31 on Monday. The company has a current ratio of 1.72, a quick ratio of 1.24 and a debt-to-equity ratio of 0.54. The company has a market capitalization of $12,015.12, a price-to-earnings ratio of -9.31, a price-to-earnings-growth ratio of 1.82 and a beta of 0.76. Perrigo Company plc has a 12-month low of $63.68 and a 12-month high of $95.93.
TRADEMARK VIOLATION NOTICE: This piece was originally published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.thelincolnianonline.com/2018/02/12/perrigo-company-plc-prgo-shares-sold-by-cooke-bieler-lp.html.
Perrigo Company Profile
Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.
Want to see what other hedge funds are holding PRGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Perrigo Company plc (NYSE:PRGO).
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.